Skip to main content

Month: December 2024

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that it has sold its FC2 Female Condom® (Internal Condom) business to clients managed by Riva Ridge Capital Management LP, a New York City-based investment management firm as well as other co-investors, for $18 million, subject to adjustment as set forth in the purchase agreement. “The monetization of the FC2 business allows Veru to be a pure biopharmaceutical company focusing its additional nondilutive resources on the execution and development of its promising late-stage clinical drug pipeline,” said Mitchell Steiner, M.D., Chairman, President,...

Continue reading

Halcones Precious Provides Update on Option Agreement to Acquire the Polaris Project

TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) — Halcones Precious Metals Corp. (TSXV: HPM) (the “Company” or “Halcones”) announces that further to its news release dated October 28, 2024, the Company has entered into a letter agreement dated December 18, 2024 (the “New Agreement”) between the Company and Austral Exploraciones SpA (“Austral”). The New Agreement supersedes the original letter agreement dated October 25, 2024 (the “Original Agreement”) between the Company and the shareholders of Austral and the Original Agreement has been terminated. Pursuant to New Agreement, Austral and Halcones have agreed to reduce the number of Halcones shares issued at closing and space out the issuance of Halcones shares over time. The 50 million Halcones shares originally scheduled to be issued at closing of the option transaction (the “Polaris...

Continue reading

AITX’s 2024 Review Sets Up 2025 For Continued Strong Growth & Profitability

Detroit, Michigan, Dec. 31, 2024 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCPK:AITX), a global leader in AI-driven security and productivity solutions for enterprise clients, today announced that CEO Steve Reinharz has shared insights on the Company’s pivotal achievements in calendar year 2024. In a video message released earlier today, Reinharz detailed AITX’s extraordinary growth and achievements in 2024, highlighted by exponential increases in total revenue and recurring monthly revenue for the third consecutive year. This sustained growth reflects the Company’s ability to consistently scale its operations while delivering significant value to clients. Reinharz attributed these results to AITX’s unwavering commitment to innovation, operational efficiency, and its mission to...

Continue reading

Vireo Growth Inc. Announces Closing of Oversubscribed US$81 Million Equity Securities Offering

– Oversubscribed equity raise at US$0.625 per share capitalizes Company with a strong balance sheet– – Financing enables Vireo to fund investments in additional organic and acquisitive growth opportunities – MINNEAPOLIS, Dec. 31, 2024 (GLOBE NEWSWIRE) — Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today announced that on December 30, 2024, it closed the previously-announced private placement offering of Subordinate Voting Shares of the Company (the “Offering”). Investors who participated in the Offering subscribed for 129,536,874 Subordinate Voting Shares at a share price of US$0.625, a 16.8% premium to the closing share price on the OTCQX on December 27, 2024. The Offering raised gross proceeds of approximately US$81 million, which includes a portion of the oversubscribed...

Continue reading

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuations Enrollment to be extended due to low influenza infection among challenged participants; virology results are uninterpretableBOTHELL, Wash., Dec. 31, 2024 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces plans to extend enrollment in the Phase 2a human challenge study with its investigational, broad-spectrum, oral influenza PB2 inhibitor CDI-42344 due to unexpectedly low influenza infection among study participants who were challenged with a H3N2 viral strain. This randomized, double-blind, placebo-controlled Phase 2a study is evaluating the safety, tolerability, pharmacokinetics (PK), antiviral activity and clinical measurements of CC-42344 at a single...

Continue reading

Spectral AI Provides Instructions for Retail Investors on Exercising Publicly-Traded Warrants

DALLAS, Dec. 31, 2024 (GLOBE NEWSWIRE) — Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced instructions for retail investors on how to exercise any publicly-traded warrants (NASDAQ: MDAIW). The warrant exercise process includes the following steps:Contact Your Brokerage Firm. You should contact your broker’s corporate actions department to initiate the warrant exercise process. Ensure Sufficient Funds in your Brokerage account. You will need to confirm that your brokerage account has adequate funds to cover the exercise price of $2.75 per warrant, plus any applicable fees. Submit Exercise Request to your...

Continue reading

Refined Energy Corp. Announces Option Grant to Advisory Board Members

VANCOUVER, British Columbia, Dec. 31, 2024 (GLOBE NEWSWIRE) — Refined Energy Corp. (CSE: RUU; OTC: RFMCF; FRA: CWA0) (the “Company”) announces that it has granted 200,000 stock options (“Options”) pursuant to the Company’s equity incentive plan (the “Plan”), each with an exercise price of CDN $0.15, to Rock U Consulting, a corporation held by Ken Wheatley, an experienced professional geoscientist, and James des Cognets, a mining industry veteran, who have agreed to join the Company’s advisory board. Such options will vest in equal installments on each of April 19, 2025, August 19, 2025, December 19, 2025, and April 19, 2026, and shall expire December 19, 2026. Each vested Option, upon satisfaction of the exercise price, entitles the holder thereof to receive one common share of the Company. The Options are subject to the terms...

Continue reading

PodcastOne (PODC) Announces Virtual Investor Webinar on January 16, 2025, at 11:00 a.m. EST

Please Join Management for an Interactive Presentation with Question-and-Answer Session LOS ANGELES, Dec. 31, 2024 (GLOBE NEWSWIRE) — PodcastOne (NASDAQ: PODC), a leading publisher and podcast sales network, announced today that it will hold a virtual investor webinar to discuss its business operations and recent successes. The event is open to all interested investors and stakeholders. PodcastOne executive management including President Kit Gray, Chief Financial Officer Aaron Sullivan, and Vice Chairman Steve Lehman will provide an overview of the business, discuss its strategic direction, and highlight the momentum behind the recent expansion of the programming slate to 194 shows and surpassing 3.8 billion network downloads. The webinar will include the management presentation followed by a question-and-answer session, which...

Continue reading

Heritage Distilling Names Michael P. Carrosino as Chief Financial Officer

Veteran finance executive with more than 40 years’ experience to lead Heritage’s financial operations and manage capital market transactions GIG HARBOR, Wash., Dec. 31, 2024 (GLOBE NEWSWIRE) — Heritage Distilling Company, Inc. (NASDAQ: CASK) (“HDC” or “Heritage” or “The Company,”) a leading craft distiller of innovative premium brands, announced the appointment of Michael P. Carrosino as its Chief Financial Officer (CFO). A veteran finance executive with over 40 years’ experience, Mr. Carrosino will be responsible for leading the Company’s financial planning and operations, managing liquidity, directing capital planning and guiding capital market transactions to ensure Heritage is well positioned to execute its expansion strategy. Justin Stiefel, Chief Executive Officer of HDC, commented, “We...

Continue reading

AmpliTech Group Releases Letter To Shareholders

HAUPPAUGE, N.Y., Dec. 31, 2024 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, today announced the release of a Letter to Shareholders from its CEO/CTO Mr. Fawad Maqbool. Dear Shareholders of Amplitech Group: As we conclude another year, I would like to express my heartfelt gratitude to all our faithful shareholders for your unwavering support. Since our IPO in 2021, AmpliTech has remained steadfast in executing our five-year strategic plan, and your trust has been integral to our success. In alignment with the roadmap outlined...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.